ePrints

Antibody engineering to develop new antirheumatic therapies

Lookup NU author(s): Professor John IsaacsORCiD

Downloads

• Published version [.pdf]

Abstract

There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immunosuppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments.

Publication metadata

Author(s): Isaacs JD

Publication type: Review

Publication status: Published

Journal: Arthritis Research & Therapy

Year: 2009

Volume: 11

Issue: 3

Pages: 225

ISSN (print): 1478-6354

ISSN (electronic): 1478-6362

Publisher: BIOMED CENTRAL LTD

URL: http://dx.doi.org/10.1186/ar2594

DOI: 10.1186/ar2594

Share